Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.83% | -5.19% | -10.35% | -6.20% | -1.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.83% | -5.19% | -10.35% | -6.20% | -1.91% |
| Cost of Revenue | -0.34% | -3.60% | -7.00% | -5.57% | -2.91% |
| Gross Profit | -1.10% | -6.11% | -12.23% | -6.57% | -1.33% |
| SG&A Expenses | 0.34% | -6.27% | -13.99% | -6.52% | -2.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 79.27% | 9.40% | 12.90% | -271.40% | -165.69% |
| Total Operating Expenses | 0.33% | -5.03% | -10.82% | -7.15% | -3.70% |
| Operating Income | -5.04% | -5.81% | -8.60% | -2.59% | 5.21% |
| Income Before Tax | -5.73% | -19.16% | -20.44% | -11.50% | 14.82% |
| Income Tax Expenses | -6.86% | -8.27% | -2.16% | -14.72% | 6.08% |
| Earnings from Continuing Operations | -5.22% | -23.46% | -27.38% | -9.96% | 19.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -658.30% | -658.30% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.57% | -0.01% | -1.45% | -36.20% | -10.15% |
| EBIT | -5.04% | -5.81% | -8.60% | -2.59% | 5.21% |
| EBITDA | -4.38% | -4.80% | -7.77% | -0.11% | 7.58% |
| EPS Basic | 28.39% | -2.93% | -5.83% | -38.62% | -11.63% |
| Normalized Basic EPS | -6.58% | -20.25% | -22.56% | -15.73% | 11.29% |
| EPS Diluted | 28.39% | -2.93% | -5.83% | -38.62% | -11.63% |
| Normalized Diluted EPS | -6.58% | -20.25% | -22.56% | -15.73% | 11.29% |
| Average Basic Shares Outstanding | 1.10% | 1.42% | 2.90% | 4.39% | 3.02% |
| Average Diluted Shares Outstanding | 1.10% | 1.42% | 2.90% | 4.39% | 3.02% |
| Dividend Per Share | -45.00% | -12.88% | -19.34% | 207.39% | 73.91% |
| Payout Ratio | 0.41% | 0.04% | -0.02% | 0.39% | -0.29% |